<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="637">
  <stage>Registered</stage>
  <submitdate>11/08/2005</submitdate>
  <approvaldate>11/08/2005</approvaldate>
  <nctid>NCT00130312</nctid>
  <trial_identification>
    <studytitle>Effect of Sulodexide in Overt Diabetic Nephropathy</studytitle>
    <scientifictitle>The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KRX-101-401</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetic Nephropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Sulodexide

Experimental: Sulodexide - Also known as KRX-101. These patients are also on standard of care ACEs and ARBs.

Placebo Comparator: Placebo - These patients were on standard of care ACEs and ARBs.


Treatment: drugs: Sulodexide


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to doubling of the serum creatinine or end stage kidney disease (ESRD) - Time in study depended on time to doubling of serum creatinine and when the patient was enrolled in the trial.</outcome>
      <timepoint>Time in study depended on time to doubling of serum creatinine</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety and tolerance of sulodexide therapy long-term - Review of laboratory parameters, adverse events, physical examinations, etc. were made to evaluate patient safety.</outcome>
      <timepoint>Time in study depended on time to doubling of serum creatinine</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in urinary protein/albumin excretion - Review of urinary protein and albumin excretion was made as an additional assessment of kidney function.</outcome>
      <timepoint>Time in study depended on time to doubling of serum creatinine</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of type 2 diabetes;

          -  Urine protein to creatinine ratio (PCR) equal to or greater than 900 mg/G (101.7
             mg/mmol) in women and equal to or greater than 650 mg/G (73.45 mg/mmol) in men;

          -  Serum creatinine in women 1.3 - 3.0 mg/dL (115-265 µmol/L), inclusive, and in men 1.5
             - 3.0 mg/dL (133-265 µmol/L), inclusive;

          -  Willing to discontinue antihypertensive medication regimen, if applicable;

          -  Willing and able to give informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Type 1 (insulin-dependent; juvenile onset) diabetes;

          -  Renal disease as follows:

               -  Patients with known non-diabetic renal disease (nephrosclerosis superimposed on
                  diabetic nephropathy acceptable), or

               -  Renal allograft;

          -  Absolute requirement for combination therapy of angiotensin converting enzyme
             inhibitors (ACEI) and angiotensin receptor blockers (ARB);

          -  Patients who require ACEI, but not ACEI/ARB combination;

          -  Cardiovascular disease as follows:

               -  Unstable angina pectoris within 3 months of study entry;

               -  Myocardial infarction, coronary artery bypass graft surgery, or percutaneous
                  transluminal coronary angioplasty/stent within 3 months of study entry;

               -  Transient ischemic attack within 3 months of study entry;

               -  Cerebrovascular accident within 3 months of study entry;

               -  New York Heart Association Functional Class III or IV (Note: if a patient is New
                  York Heart Association Functional Class I or II and requires an ACEI, consult
                  with the Clinical Coordinating Center to obtain permission for the patient to be
                  on an ACEI rather than an ARB);

               -  Obstructive valvular heart disease or hypertrophic cardiomyopathy; or

               -  Second or third degree atrioventricular block not successfully treated with a
                  pacemaker;

          -  Need for chronic (&gt;2 weeks) immunosuppressive therapy, including corticosteroids
             (excluding inhaled or nasal steroids);

          -  New diagnosis of cancer or recurrent cancer within 5 years of screening (except
             non-melanoma skin cancer);

          -  Psychiatric disorder that interferes with the patient's ability to comply with the
             protocol;

          -  Inability to tolerate oral medication or a history of significant malabsorption;

          -  History of alcohol or other drug abuse within 12 months of study entry;

          -  Known human immunodeficiency virus disease;

          -  Any other medical condition which renders the patient unable to or unlikely to
             complete the study, or which would interfere with optimal participation in the study
             or produce significant risk to the patient;

          -  Receipt of any investigational drugs (including placebo) within 30 days of enrollment;

          -  Evidence of hepatic dysfunction including total bilirubin &gt;2.0 mg/dL (&gt;35 micromol/L)
             or liver transaminase (aspartate aminotransferase [AST] or alanine transferase [ALT])
             &gt;3 times upper limit of normal;

          -  Anticipate need for surgery;

          -  Inability to cooperate with study personnel or history of noncompliance to medical
             regimen;

          -  Known allergies or intolerance to any heparin-like compound including heparin-induced
             thrombocytopenia Type II;

          -  Prior exposure to sulodexide, either in a clinical setting or as a participant in
             another clinical study.

          -  Untreated urinary tract infection that would impact urinary protein values.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1248</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Collaborative Study Group, Clinical Coordinating Center for the Pacific Region, Monash Medical Center - Clayton / Melbourne</hospital>
    <postcode>3168 - Clayton / Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Keryx Biopharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Collaborative Study Group (CSG)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether sulodexide is effective in slowing or
      preventing the progression of diabetic kidney disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00130312</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Edmund J Lewis, MD</name>
      <address>The Collaborative Study Group, Rush University Medical Center, Chicago, IL USA</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>